FDA Clears Ultragenyx's GENGLYCOS Gene Therapy for GSDIa
RARE sits 71% above its 52-week low of $18.29.
Summary
FDA approval of Ultragenyx's GENGLYCOS gene therapy for GSDIa marks a major regulatory win, opening a new commercial market and validating the company's gene therapy platform.
Updates
· Wiseek News — Ultragenyx priced GENGLYCOS at $2.7M and will launch within 30-60 days, with a 10-year Disease Monitoring Program.
Key Events · Product Development and Regulatory · RARE
-
FDA Approves GENGLYCOS
The FDA granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients 8 years and older with glycogen storage disease type Ia (GSDIa).
-
Phase 3 Data Supports Approval
Approval was based on the 48-week Phase 3 GlucoGene study of 46 participants, which showed a statistically significant reduction in cornstarch requirements (p<0.001) in the treated group.
-
Post-Marketing Requirements
Ultragenyx agreed to provide 2 years of safety/efficacy data from 50 treated and 20 control patients via its GSDIa Disease Monitoring Program, with 10-year follow-up.
-
Commercial Launch Imminent
Accelerated approval allows immediate commercialization; the company can begin selling GENGLYCOS while completing post-marketing studies.
Analysis · RARE · Life Sciences
A major regulatory milestone has been reached: the FDA granted accelerated approval to GENGLYCOS (DTX401) for glycogen storage disease type Ia, a rare metabolic disorder. This decision validates the company's gene therapy platform and opens a new commercial market. The approval rests on positive Phase 3 data showing a statistically significant reduction in cornstarch requirements. Under the accelerated approval pathway, Ultragenyx must conduct post-marketing studies, but the product can be sold immediately. For a company with a $2.6B market cap and a recent history of insider selling, this is a thesis-altering event.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.9% of the 303 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RARE was trading at $31.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $18.29 to $39.89. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.